

Figure S1. Further verification of the association between TMSB10 expression level and clinicopathological factors of clear cell renal cell carcinoma in the GEO database. (A) In GSE 53757, the expression of TMSB10 increased with increasing tumor stage. (B) In GSE 40435, the expression of TMSB10 increased with increasing pathological grade. TMSB10, thymosin β 10.





Figure S2. Possible underlying mechanisms of TMSB10 in clear cell renal cell carcinoma. When the expression of TMSB10 was silenced in ACHN cells, VEGF expression and the phosphorylation of PI3K were downregulated. (A) Representative western blots are presented. Protein expression was normalized to β -actin expression. (B) The mean gray value of each group is presented as the mean \pm SD. (C) Ratio of phosphorylated to total PI3K. Tukey's test was used to analyze the differences. ** $P < 0.001$, *** $P < 0.0001$; ns, no statistical significance. TMSB10, thymosin β 10; VEGF, vascular endothelial growth factor.




Table SI. Basic characteristics of 80 patients with clear cell renal cell carcinoma.

Characteristic	Data
Age, mean \pm SEM (years)	54 \pm 12
Sex, male/female	42/38
Tumor size, mean \pm SEM (cm)	5.6 \pm 3.4
Location, right/left	33/47
T stage, n (%)	
T1a	16 (20)
T1b	13 (16.25)
T2a	27 (33.75)
T2b	11 (13.75)
T3	6 (7.5)
T4	5 (6.25)
Unknown	2 (2.5)
N stage, n (%)	
N0	72 (90.00)
N1	8 (10.00)
M stage, n (%)	
M0	74 (92.5)
M1	6 (7.5)
Fuhrman grade, n (%)	
1	16 (20.00)
2	42 (52.5)
3	12 (15.00)
4	8 (10.00)
Unknown	2 (2.5)